<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82336">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01952548</url>
  </required_header>
  <id_info>
    <org_study_id>K-312-1.01US</org_study_id>
    <nct_id>NCT01952548</nct_id>
  </id_info>
  <brief_title>Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Research Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Research Institute, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test single doses of the study drug in increasing amounts to see if it is
      safe.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>10 Days</time_frame>
  </primary_outcome>
  <condition>Safety and Tolerability</condition>
  <arm_group>
    <arm_group_label>Dose 1 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 6 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 7 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 6 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 7 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-312</intervention_name>
    <arm_group_label>Dose 1 Active</arm_group_label>
    <arm_group_label>Dose 2 Active</arm_group_label>
    <arm_group_label>Dose 3 Active</arm_group_label>
    <arm_group_label>Dose 4 Active</arm_group_label>
    <arm_group_label>Dose 5 Active</arm_group_label>
    <arm_group_label>Dose 6 Active</arm_group_label>
    <arm_group_label>Dose 7 Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Dose 1 Placebo</arm_group_label>
    <arm_group_label>Dose 2 Placebo</arm_group_label>
    <arm_group_label>Dose 3 Placebo</arm_group_label>
    <arm_group_label>Dose 4 Placebo</arm_group_label>
    <arm_group_label>Dose 5 Placebo</arm_group_label>
    <arm_group_label>Dose 6 Placebo</arm_group_label>
    <arm_group_label>Dose 7 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject provides written informed consent before any study-specific evaluation is
             performed.

          -  Subject is a healthy adult male or a female of non-childbearing potential between the
             ages of 18 and 45 years, inclusive.

          -  Subject has a body mass index of 18.5 to 32 kg/m2, inclusive.

        Exclusion Criteria:

          -  Subject is a woman who is of childbearing potential or is breastfeeding.

          -  Subject has the presence of an active or recurring clinically significant
             cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric,
             immunologic, hematologic, gastrointestinal, or metabolic disease requiring medical
             treatment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 30, 2013</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
